Stock 1801 INNOVENT BIOLOGICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Innovent Biologics, Inc.

Equities

1801

KYG4818G1010

Market Closed - Hong Kong S.E.
Other stock markets
 01:38:20 26/04/2024 pm IST 		5-day change 1st Jan Change
39.15 HKD +1.56% Intraday chart for Innovent Biologics, Inc. +17.92% -8.42%
17/04 Innovent Appoints Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer CI
02/04 Hutchmed endometrial cancer treatment application accepted for review AN

Evolution of the average Target Price on Innovent Biologics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

9592c4db3b0914662cd5952810b.OuUjvXHmJ2uCEXHSqBasVFiCh0SFyQP7mpV-ORvUgik.fJ9s1TeURifBUkC5kFLKMzeztgGxo1CR0eUnQ035z2BSjnD0M4geCMBbAg~6d5bb76a60bbaf39fe0c2c5bf51afe7d

Analyst Recommendations on Innovent Biologics, Inc.

Nomura Adjusts Innovent Biologics’ Price Target to HK$55.31 From HK$54.51, Keeps at Buy MT
Nomura Adjusts Innovent Biologics’ Price Target to HK$54.51 From HK$45.73, Keeps at Buy MT
Nomura Adjusts Innovent Biologics' Price Target to HK$45.73 From SG$54.72, Keeps at Buy MT
Nomura Adjusts Innovent Biologics' Price Target to HK$54.72 From HK$45.44, Keeps at Buy MT
Nomura Adjusts Innovent Biologics' Price Target to HK$45.44 From HK$45.38, Keeps at Buy MT
UBS Adjusts Innovent Biologics' Price Target to HK$42 From HK$39.30, Keeps at Buy MT
Nomura Adjusts Innovent Biologics' Price Target to HK$45.38 From HK$43.75, Keeps at Buy MT
Hong Kong stocks down as tech shares slide ahead of Fed rate decision RE
Nomura Adjusts Innovent Biologics' Price Target to HK$43.75 From HK$49.41, Keeps at Buy MT
UBS Adjusts Innovent Biologics' Price Target to HK$43 From HK$60, Keeps at Buy MT
Nomura Adjusts Innovent Biologics' Price Target to HK$49.41 From HK$58.18, Keeps at Buy MT
Nomura Adjusts Innovent Biologics Price Target to HK$58.18 From HK$92.73, Keeps at Buy MT
Tech stocks drag Hong Kong shares lower on U.S. rate hike concerns RE
INNOVENT BIOLOGICS : Nomura Adjusts Innovent's Price Target to HK$113.4 From HK$66.3, Keeps at Buy MT
Innovent Announces Parsaclisib Treatment Results in High Rate of Rapid and Durable Responses in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas CI
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
36.24 CNY
Average target price
51.18 CNY
Spread / Average Target
+41.23%
High Price Target
71.04 CNY
Spread / Highest target
+96.03%
Low Price Target
34.05 CNY
Spread / Lowest Target
-6.04%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Innovent Biologics, Inc.

Nomura
UBS

Ratings for Innovent Biologics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. 1801 Stock
  4. Consensus Innovent Biologics, Inc.